BioPortoDx

It’s #WorldKidneyDay, marking 20 years of championing kidney health worldwide. 1 in 10 people live with kidney disease. Most don’t know it. Early detection saves lives - and protects the healthcare systems we all depend on. #OurKidneysOurPlanet #KidneyHealth #AKI

AKI is common in children treated w/extracorporeal membrane oxygenation (ECMO) & is associated w/increased morbidity & mortality. AKI may also increase risk of long-term CKD. Read this Original Article on kidney & BP sequelae after pediatric ECMO. link.springer.com/article/10.100…

Warmest wishes for a bright and peaceful holiday season.

@PittHealthSci Wonderful to see an innovator in the critical care kidney space being honored. We appreciate @kellumja as a clinician, scientist, and collaborator in the AKI field.

#PittMed’s John Kellum elected Fellow of the National Academy of Inventors — recognized for innovations that bridge science and patient impact. bit.ly/3Mw9d49

A recent study led by @ptdmurray in Ireland found that urinary NGAL testing improved the ability to distinguish between intrinsic and non-intrinsic AKI, addressing a key limitation of serum creatinine. Using a threshold of NGAL < 150 ng/ml effectively "rules out" intrinsic AKI, allowing clinicians to focus on functional (pre-renal) or obstructive (post-renal) causes when NGAL is negative. #NGAL #AKI #BioPortoMedAffairs Read more about this study: pubmed.ncbi.nlm.nih.gov/40802457/ @svuh, @ASNKidney360

Still relying on serum creatinine to identify patients with AKI? Visit us today and tomorrow in the exhibit hall at the Canadian Critical Care Forum (Table 16) to learn how NGAL testing can help you manage AKI earlier. #ICU #Critical Care #CCCF2025 @CCCForum

As we reflect on another year of success, we extend our heartfelt gratitude to our incredible employees, loyal customers, dedicated investors, collaborators, researchers, and clinicians — and to the impact our NGAL products have in advancing patient care and kidney health. Thank you!

Attending the Canadian Critical Care Forum? Come visit us at booth #16 to discuss how the NGAL biomarker can help improve outcomes for critically-ill patients. BioPorto attendees: Matt Grimmig and Sheila Schwabe

Attending American Society of Nephrology's annual meeting this November? Let's connect - visit us at booth 1342. #ASN2025 #NGAL @JenZ4NGAL

@csc_wodarz and @JenZ4NGAL are excited to join the intensive care community for @ESICM #LIVES2025 in Munich. Connect with them in one of the many #AKI sessions or at booth 3.04. Learn how the NGAL biomarker and The NGAL Test can help you identify AKI earlier in your critically ill patients. #CriticalCare #ICU @ESICM, @ISICEM, @ICCNursJournal, @ESPNIC_Society, @yourICM

Don’t miss the chance to meet three clinical experts from 3 countries and learn how they are using the NGAL biomarker to detect and manage acute kidney injury earlier in their patients. #NGAL4kids #ESPN2025 #PedsNephrology @slgold777

Let’s connect at #PCICS2025 to talk about AKI in your pediatric cardiac patients. Visit table 33 to learn how ProNephro AKI (NGAL) can help identify AKI risk earlier. #PCICU #NGAL4kids Attendees: @JenZ4NGAL @nikole_relich, Jay Rohela and Ray White II

Discover how the NGAL biomarker is transforming pediatric care – one child at a time, across continents. Join us at #ESPN2025 booth 26 for an exclusive ""Meet the Experts"" session with NGAL experts @slgold777 (USA), Jun Oh (Germany), and Giovanni Ceschia (Italy). They will share real-world pediatric cases highlighting the role of NGAL in early kidney injury detection and management. #NGAL4kids #PediatricNephrology Oct 17 10:30-11:00 ESPN 2025, Stand 26"

Attending #PCICS2025? Visit us at table 33 to learn about ProNephro AKI (NGAL) – the first test for AKI risk assessment in ICU patients 3 months to 22 years. #NGAL4kids #PedsICU @PCICS2

Attending #PCICS2025? Visit us at table 33 to learn about ProNephro AKI (NGAL) – the first test for AKI risk assessment in ICU patients 3 months to 22 years. #NGAL4kids #PedsICU @PCICS2

The results of this study by Drs. Giovanni Ceschia, @slgold777, et al, strongly suggest that the #NGAL biomarker is a valuable tool to support decisions in pediatric #AKI management, while addressing a critical gap in CKST discontinuation protocols. Read more for cutoffs and results: nature.com/articles/s4139… @Ped_Research #PedsICU #NGAL4kids "

@JenZ4NGAL Thanks to @IptaPedsTx for the opportunity to share how an NGAL result can help identify AKI in pediatric patients post-transplant. #NGAL4kids

@BioPortoDx Thank you to the hundreds of attendees for this webinar!

Just announced! BioPorto is sponsoring a U.S. News & World Report webinar: “New Frontiers in Kidney Care” – Sept 11 at 1PM ET Join leading kidney experts to explore how innovation is improving outcomes for both acute and chronic kidney conditions. Register free here: lnkd.in/d64idJ_w #KidneyCare #NGAL #AKI #CKD #Nephrology #BioPorto #Webinar

The BioPorto team is excited to be part of the 5th International Symposium on AKI in Children hosted by Cincinnati Children's Hospital. We celebrate the research and clinical innovations of nephrology, cardiac and critical care teams dedicated to improving pediatric AKI management. Visit us in the exhibit hall, connect with us in a session or schedule some time to meet BioPorto's new CEO, Carsten Buhl. @slgold777 @aakashdeeparora

Excited to join the #MSPR Annual Meeting this week. We look forward to learning about all the new pediatric research, especially as it relates to #AKI and urine biomarkers. Visit us in the exhibit hall to share your latest research.

We’re thrilled to welcome Carsten Buhl as the new CEO of BioPorto! Carsten’s leadership will be instrumental in launching ProNephro AKI (NGAL)™ in the US market, driving revenue growth and finalizing the clinical studies & submitting an FDA application for adult use in 2026.